PDMR Dealing and ESOT Share Purchase
Cellbxhealth plc announced that Executive Chairman Jan Groen and Chief Executive Officer Peter Collins each purchased 5,000,000 ordinary shares at 1.0 pence per share, and Finance Director Sinead Armstrong acquired 2,500,000 ordinary shares at the same price, following an oversubscribed placing. Additionally, the trustee of the ANGLE Employee Share Ownership Trust purchased 2,886,742 ordinary shares at 1.1p each, which will be held for employee benefit. Following these transactions, Dr. Groen and Mr. Collins hold approximately 0.4% of the company's issued share capital, and Mrs. Armstrong holds approximately 0.2%, while the ESOT will hold 3,000,000 shares, representing 0.3%.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK - 19 December 2025 - CELLBXHEALTH plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, announces that, following the Oversubscribed Placing and Subscription announced on the 25 November 2025, Executive Chairman, Jan Groen and Chief Executive Officer Peter Collins each acquired 5,000,000 Ordinary Shares in the Company. In addition, Sinead Armstrong, Finance Director acquired 2,500,000 Ordinary Shares in the Company. All shares were purchased at a price of 1.0 pence, being the Placing Price.
Following the transaction, Dr Groen's and Mr Collins' aggregate direct and indirect ultimate beneficial interest in the Company's Ordinary Shares is 5,000,000 representing approximately 0.4% of the Company's currently issued share capital, Mrs Armstrong's aggregate direct and indirect ultimate beneficial interest in the Company's Ordinary Shares is 2,596,056 representing approximately 0.2% of the Company's currently issued share capital.
Employee Share Ownership Trust Share Purchase
Furthermore, the Company announces that Zedra Trust Company (Guernsey) Ltd, acting as trustee of the ANGLE Employee Share Ownership Trust (the "ESOT"), purchased, earlier today, a total of 2,886,742 ordinary shares in the Company at a price of 1.1p each.
The shares will be held in the ESOT, which is a discretionary trust for the benefit of the Company's employees and will ultimately be used to satisfy share awards and options granted under the Company's various share incentive arrangements.
The ESOT may be used to assist in meeting the obligations under employee remuneration schemes with Executive Directors and Persons Discharging Managerial Responsibility of the Company, together with other employees, as potential beneficiaries and are therefore treated as having an interest in some of those shares and the dealings thereof.
Immediately following settlement of the above transaction, the ESOT will hold 3,000,000 ordinary shares ("ESOT Shares") representing 0.3% of the Company's issued share capital.
The Company's issued share capital as at 19 December 2025 consists of 1,139,402,658 ordinary shares of 0.05 pence each with voting rights. The Company does not hold any shares in treasury and has waived its right to exercise its voting rights and to receive dividends in respect of the EBT Shares. Therefore, the total number of voting rights is 1,136,402,658.
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Announcement on 24 November 2025.
The Company's LEI is 213800BY11K6W3NMS374
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | a) Jan Groen b) Peter Collins c) Sinéad Armstrong |
| 2 | Reason for the notification | |
| a) | Position/status | a) Jan Groen (Chairman) b) Peter Collins (CEO) c) Sinéad Armstrong (FD) |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | CelLBxHealth Plc |
| b) | LEI | 213800BY11K6W3NMS374 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.05 pence value each |
| Identification code | GB0034330679 | |
| b) | Nature of the transaction | a) Jan Groen - Purchased 5,000,000 Ordinary Shares b) Peter Collins - Purchased 5,000,000 Ordinary Shares c) Sinead Armstrong - Purchased 2,500,000 Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| a) 1p b) 1p c) 1p | a) 5,000,000 b) 5,000,000 c) 2,500,000 | |
| d) | Aggregated information | |
| - Aggregated volume | n/a, each a single transaction | |
| - Price | n/a, each a single transaction | |
| e) | Date of the transaction | 18 December 2025 |
| f) | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.